Full Press Release Details
Pharmaceuticals to Present at the 2015 Rodman & Renshaw 17th Annual
Global Investment Conference
VICTORIA, British Columbia--(BUSINESS WIRE)--September 2, 2015--Aurinia
Pharmaceuticals Inc., (NASDAQ:AUPH; TSX:AUP) today announced that its
President and Chief Executive Officer, Stephen W. Zaruby, will present a
corporate overview of the Company at the 2015 Rodman & Renshaw 17th
Annual Global Investment Conference, taking place September 8th
- 10th, 2015 in New York at The St. Regis Hotel.
Aurinia Presentation Details
| Date: | Wednesday, September 9th, 2015 | ||
| Time: | 10:25 a.m. Eastern time | ||
| Location: | New York, The St. Regis Hotel - Louis XVI A Room | ||
| Webcast: | http://www.wsw.com/webcast/rrshq25/auph |
Aurinia is a clinical stage pharmaceutical company focused on the global
nephrology market. It is currently in the recruitment and enrollment
phase of its Phase 2b clinical trial to evaluate the efficacy of its
drug, voclosporin, as a treatment for lupus nephritis (LN). LN is an
inflammation of the kidneys, that if inadequately treated can lead to
end-stage renal disease, making LN a serious and potentially
life-threatening condition.
Visit www.auriniapharma.com for more information.
Aurinia Pharmaceuticals Inc.
President & Chief Executive Officer
Michael R. Martin, 250-708-4272